Accuray（ARAY）株式概要
Accuray Incorporatedは、米国、カナダ、ラテンアメリカ、オーストラリア、ニュージーランド、欧州、中東、インド、アフリカ、日本、中国において、全身の腫瘍治療用の放射線外科および放射線治療システムの設計、開発、販売を行っている。 詳細
ARAY Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Accuray Incorporated 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$0.25 |
| 52週高値 | US$2.10 |
| 52週安値 | US$0.22 |
| ベータ | 1.39 |
| 1ヶ月の変化 | -10.06% |
| 3ヶ月変化 | -25.40% |
| 1年変化 | -84.46% |
| 3年間の変化 | -90.77% |
| 5年間の変化 | -92.87% |
| IPOからの変化 | -99.12% |
最新ニュース
Recent updates
ナラティブ更新 • Jun 26
ARAY: Reset P/E Expectations And Guidance Withdrawal Will Shape Future Risk Balance
The analyst price target on Accuray has been cut by about $3.53 to reflect a lower implied fair value, a higher discount rate, and sharply reduced future P/E expectations, following recent downgrades where analysts cited softer growth and margin assumptions. Analyst Commentary Recent research on Accuray has focused on how realistic growth and margin assumptions should feed into valuation, especially after the latest downgrades and the reset in future P/E expectations.分析記事 • May 13
Need To Know: Analysts Just Made A Substantial Cut To Their Accuray Incorporated (NASDAQ:ARAY) Estimates
Today is shaping up negative for Accuray Incorporated ( NASDAQ:ARAY ) shareholders, with the analysts delivering a...
新しいナラティブ • Feb 21
Future Service Contracts And Operational Transformation Will Reshape Long Term Cancer Care Access
Catalysts About Accuray Accuray develops and sells radiation therapy systems and related services used by hospitals and cancer centers worldwide. What are the underlying business or industry changes driving this perspective?分析記事 • Feb 06
The Market Doesn't Like What It Sees From Accuray Incorporated's (NASDAQ:ARAY) Revenues Yet As Shares Tumble 33%
Unfortunately for some shareholders, the Accuray Incorporated ( NASDAQ:ARAY ) share price has dived 33% in the last...Seeking Alpha • Feb 06
Groundhog Day Once Again, As Accuray Misses And Lowers
Summary Accuray continues to disappoint with weaker revenue, weaker orders and market share, lowered guidance, and little evidence of a turnaround. ARAY's restructuring aims for $25M in annual profitability improvements, but lacks novel strategies and may risk further sales declines. Competitive pressure from Siemens Healthineers and Elekta underscores ARAY's inability to gain traction, especially in critical markets like China. Despite undervaluation, persistent cash burn and lack of turnaround visibility make the risk/reward unattractive; I plan to exit my small position. Read the full article on Seeking Alpha
新しいナラティブ • Feb 06
Service Transformation And China Delays Will Reshape Margins Yet Eventually Support A Healthier Business
Catalysts About Accuray Accuray develops and sells radiation therapy systems and related services for cancer treatment facilities worldwide. What are the underlying business or industry changes driving this perspective?分析記事 • Dec 20
Accuray (NASDAQ:ARAY) May Have Issues Allocating Its Capital
If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...分析記事 • Dec 02
Little Excitement Around Accuray Incorporated's (NASDAQ:ARAY) Revenues As Shares Take 28% Pounding
The Accuray Incorporated ( NASDAQ:ARAY ) share price has fared very poorly over the last month, falling by a...分析記事 • Nov 27
Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Oct 10
Benign Growth For Accuray Incorporated (NASDAQ:ARAY) Underpins Its Share Price
Accuray Incorporated's ( NASDAQ:ARAY ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy...分析記事 • Aug 13
Returns At Accuray (NASDAQ:ARAY) Are On The Way Up
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...分析記事 • Jun 28
Accuray Incorporated's (NASDAQ:ARAY) Share Price Is Matching Sentiment Around Its Revenues
With a price-to-sales (or "P/S") ratio of 0.3x Accuray Incorporated ( NASDAQ:ARAY ) may be sending very bullish signals...分析記事 • Apr 04
Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...分析記事 • Mar 11
Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 26% Price Drop
Accuray Incorporated ( NASDAQ:ARAY ) shares have had a horrible month, losing 26% after a relatively good period...分析記事 • Jan 18
Accuray Incorporated (NASDAQ:ARAY) Shares Fly 25% But Investors Aren't Buying For Growth
Accuray Incorporated ( NASDAQ:ARAY ) shares have had a really impressive month, gaining 25% after a shaky period...Seeking Alpha • Jan 07
Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'
Summary Impressive revenue growth remains elusive for Accuray despite the potential in China, and there are ongoing challenges with profitability, competition, and market scale. The last quarter's results showed mixed performance, with better than expected revenue and a small guidance boost, but overall product sales were down and the backlog shrank modestly. Sustainability remains a key issue; China is growing nicely, but revenue in Japan weakened and the company has seen its installed base in the U.S. shrink, pressuring service revenue. Accuray appears undervalued but faces significant risks; the potential for better results exists, particularly if China efforts succeed and U.S. sales stabilize, but improvement in execution has long been elusive. Read the full article on Seeking Alpha分析記事 • Dec 19
Health Check: How Prudently Does Accuray (NASDAQ:ARAY) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Dec 05
Accuray Incorporated: Cheap, But With Caveats
Summary Today, we take a deeper look at Accuray Incorporated, a medical device company that manufactures radiosurgery and radiation therapy systems. Despite mid-single-digit sales growth, Accuray trades at under 50% of current revenues and is nearing profitability, but the company has a significant debt load. A couple of analyst firms believe the stock should be trading at much higher levels. An analysis around Accuray Incorporated follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Aug 18
Accuray Remains A Perpetual 'Next Year Is Our Year' Story
Summary Accuray posts a strong end to the fiscal year with 16% revenue growth in FQ4, beating expectations and restoring some confidence for the upcoming year. Management's claim that weaker U.S. sales are a consequence of a weaker capex environment don't fully align with the reported U.S. sales results of other med-tech capital equipment companies. Global opportunities remain promising, especially in China's value-priced linac market, and opportunities in Japan, India, other emerging markets are meaningful. Execution remains critical as the company faces tough competition and needs to capitalize on growth opportunities in China and replacement/renewal opportunities in the U.S. market. Accuray shares offer potential upside, at the cost of elevated risk, if the company can overcome sales execution challenges and capitalize on emerging market opportunities. Read the full article on Seeking Alpha分析記事 • Aug 13
Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues
Accuray Incorporated ( NASDAQ:ARAY ) shareholders won't be pleased to see that the share price has had a very rough...分析記事 • May 21
Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop
To the annoyance of some shareholders, Accuray Incorporated ( NASDAQ:ARAY ) shares are down a considerable 25% in the...分析記事 • May 04
Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results
It's shaping up to be a tough period for Accuray Incorporated ( NASDAQ:ARAY ), which a week ago released some...分析記事 • May 03
Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Accuray fair value estimate is US$2.06 Accuray's US$1.54 share...株主還元
| ARAY | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | -6.2% | -5.5% | -0.9% |
| 1Y | -84.5% | -18.1% | 13.9% |
業界別リターン: ARAY過去 1 年間で-18.1 % の収益を上げたUS Medical Equipment業界を下回りました。
リターン対市場: ARAYは、過去 1 年間で13.9 % のリターンを上げたUS市場を下回りました。
価格変動
| ARAY volatility | |
|---|---|
| ARAY Average Weekly Movement | 14.4% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: ARAYの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: ARAYの weekly volatility ( 14% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1990 | 809 | Steve LaNeve | www.accuray.com |
Accuray Incorporatedは、米国、カナダ、ラテンアメリカ、オーストラリア、ニュージーランド、ヨーロッパ、中東、インド、アフリカ、日本、中国において、全身の腫瘍治療のための放射線外科および放射線治療システムの設計、開発、販売を行っています。 同社は、CyberKnifeプラットフォームを提供しています。これは、脊椎上またはその付近、ならびに乳房、腎臓、肝臓、肺、膵臓、前立腺などの脳以外の原発性および転移性腫瘍の治療に使用される、ロボットによる定位放射線手術および定位体部放射線治療システムです。 また、同社は「TomoTherapy」プラットフォームも提供しており、これには、放射線治療計画、照射、画像診断、データ管理を統合したオーダーメイド型のヘリカルソリューションである「Radixactシステム」、治療計画とデータ管理を完全に統合した「iDMSデータ管理システム」、および治療計画・データ管理システムである「Accuray精密治療計画システム」が含まれる。 さらに、同社は契約後のカスタマーサポート、設置、トレーニング、その他の専門サービスも提供しています。製品の販売は、主に自社の販売組織を通じて病院や独立型治療施設などの顧客に直接行うほか、米国では販売代理店や共同購入組織（GPO）を通じて顧客に販売しています。また、海外では顧客への直接販売のほか、販売代理店や販売代理店を通じて販売を行っています。 Accuray Incorporatedは1990年に設立され、ウィスコンシン州マディソンに本社を置いている。
Accuray Incorporated 基礎のまとめ
| ARAY 基礎統計学 | |
|---|---|
| 時価総額 | US$29.88m |
| 収益（TTM） | -US$49.19m |
| 売上高(TTM) | US$401.95m |
0.1x
P/Sレシオ-0.6x
PER（株価収益率ARAY は割高か？
公正価値と評価分析を参照収益と収入
| ARAY 損益計算書（TTM） | |
|---|---|
| 収益 | US$401.95m |
| 売上原価 | US$290.49m |
| 売上総利益 | US$111.45m |
| その他の費用 | US$160.65m |
| 収益 | -US$49.19m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.41 |
| グロス・マージン | 27.73% |
| 純利益率 | -12.24% |
| 有利子負債／自己資本比率 | 354.6% |
ARAY の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/14 09:57 |
| 終値 | 2026/09/11 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2026/06/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Accuray Incorporated 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16
| アナリスト | 機関 |
|---|---|
| Neil Chatterji | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |